Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, had its shares halted from trading pending an announcement.
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
Most listened to
- Sunday Business Episode 26: Air New Zealand CEO Christopher Luxon
- 'Grumpy as hell' Bill Bennett says he'll use a VPN to connect to Chelsea's club channel
- “Cut the cuteness about cannabis reform” - Matthew Hooton
- Rodney Hide thinks Winston Peters will be the future Maori king
- Ethical investment in KiwiSaver - David Cohen vs. Matt Nippert